Αρχική World News Five-Year Survival Outcomes with Neoadjuvant Therapy in Melanoma Demonstrate that Neoadjuvant ICIs... World News Five-Year Survival Outcomes with Neoadjuvant Therapy in Melanoma Demonstrate that Neoadjuvant ICIs Exceeded Adjuvant Benchmarks Από Ogkologos - 13 Οκτωβρίου, 2026 79 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from updated pooled analysis Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR Marking Breast Cancer Awareness Month 2025, ESMO Calls for Increasing Awareness... 27 Οκτωβρίου, 2025 OncoArray Links Dozens of DNA Variants to Risk for Common Cancers 12 Ιουνίου, 2018 Aiming to Support Cancer Research, ESMO Calls on the European Council... 28 Αυγούστου, 2026 Take with Food: Study Tests Lowering Dose of Prostate Cancer Drug 23 Απριλίου, 2018 Φόρτωση περισσοτέρων HOT NEWS A new IARC live webinar on evidence in primary cancer prevention Adding Atezolizumab to Chemotherapy Does Not Improve Outcomes in Patients Who... EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Imatinib EMA Recommends Granting a Conditional Marketing Authorisation for Sotorasib